# Lexaria (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment

* Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs.
* GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices.
* A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®.
* Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market.

 Data from the United States shows that 54% of adults and 66% of children consume more added sugars than recommended (https://cnw.fm/JNFjW). On average, it has been noted that adults, young adults, and children in the United States consume 17 teaspoons of added sugar daily, which is more than two to three times the recommended amount for men and women, respectively. Extrapolated annually, this adds up to around 60 pounds of added sugar or six 10-pound bowling balls (https://cnw.fm/VamC5).

 Numerous studies have linked increased sugar consumption to diabetes. While not directly linked, sugar is considered integral to weight gains, which, in turn, increases their risk of type 2 diabetes. The condition cannot be cured, but it can be managed. Recent studies on glucagon-like peptide-1 (“GLP-1”) have…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

 About CBDWire

 CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

 CBDW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CBDWire.com

 Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

 CBDWireDenver, COwww.CBDWire.com303.498.7722 OfficeEditor@CBDWire.com

 CBDWire is powered by IBN 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/lexaria-nasdaq-lexx-targeting-oral-glp-1-alternatives-for-diabetes-and-obesity-treatment/) 

[Newsramp.com TLDR](https://newsramp.com/None) 